Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 51.39M | 9.06M | 6.09M | 5.76M | 5.26M |
Gross Profit | 51.39M | 9.06M | 6.09M | 5.76M | 4.96M |
EBITDA | 25.94M | -11.83M | -13.32M | -12.31M | -17.99M |
Net Income | 15.84M | -16.22M | -17.49M | -14.90M | -21.00M |
Balance Sheet | |||||
Total Assets | 63.91M | 25.87M | 37.20M | 50.49M | 51.20M |
Cash, Cash Equivalents and Short-Term Investments | 9.83M | 12.60M | 22.77M | 34.59M | 31.25M |
Total Debt | 50.47M | 48.41M | 45.66M | 43.08M | 26.34M |
Total Liabilities | 62.45M | 55.77M | 51.23M | 47.38M | 33.95M |
Stockholders Equity | 1.46M | -29.91M | -14.03M | 3.11M | 17.25M |
Cash Flow | |||||
Free Cash Flow | -17.63M | -10.15M | -11.11M | -11.46M | -15.62M |
Operating Cash Flow | -17.61M | -10.14M | -11.09M | -11.45M | -15.59M |
Investing Cash Flow | 3.16M | 3.25M | -317.00K | 8.42M | -616.00K |
Financing Cash Flow | 15.05M | -192.00K | -186.00K | 14.83M | 7.37M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $168.07M | 11.66 | ― | 450.19% | ― | ||
51 Neutral | $7.91B | -0.36 | -41.71% | 2.23% | 23.45% | -1.86% | |
― | $145.54M | ― | -48.90% | ― | ― | ― | |
65 Neutral | CHF576.14M | 7.91 | ― | 58.51% | ― | ||
51 Neutral | CHF614.71M | ― | ― | 67.18% | -480.10% | ||
― | $217.74M | 2.70 | -93.91% | ― | ― | ― | |
― | CHF118.81M | 3.55 | ― | ― | ― |
Newron Pharmaceuticals has initiated the Phase III ENIGMA-TRS program to evaluate Evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS). This international study will involve at least 600 patients and aims to provide a new treatment option for those who do not respond adequately to current antipsychotics. The study’s 12-week results are expected in Q4 2026, and it builds on previous findings that demonstrated Evenamide’s efficacy and favorable safety profile. The program’s success could significantly impact Newron’s market positioning and offer a breakthrough for TRS patients.
Newron Pharmaceuticals has announced promising preclinical research results for Evenamide, a potential treatment for schizophrenia. The study, published in Neuropsychopharmacology, highlights Evenamide’s unique mechanism of action, targeting the hyperexcitability of the hippocampus, which could improve outcomes for patients who are treatment-resistant or inadequately responsive to current antipsychotics. This development represents a significant advancement in schizophrenia treatment, potentially offering a new therapeutic strategy that addresses positive, cognitive, and negative symptoms without the side effects associated with existing antipsychotics.